Reshape Lifesciences Stock Current Liabilities
| RSLS Stock | USD 0.66 0.04 5.71% |
ReShape Lifesciences fundamentals help investors to digest information that contributes to ReShape Lifesciences' financial success or failures. It also enables traders to predict the movement of ReShape Stock. The fundamental analysis module provides a way to measure ReShape Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ReShape Lifesciences stock.
Total Current Liabilities is likely to gain to about 6 M in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 190.7 K in 2025. ReShape | Current Liabilities |
ReShape Lifesciences Company Current Liabilities Analysis
ReShape Lifesciences' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
ReShape Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for ReShape Lifesciences is extremely important. It helps to project a fair market value of ReShape Stock properly, considering its historical fundamentals such as Current Liabilities. Since ReShape Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ReShape Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ReShape Lifesciences' interrelated accounts and indicators.
Click cells to compare fundamentals
ReShape Current Liabilities Historical Pattern
Today, most investors in ReShape Lifesciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ReShape Lifesciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ReShape Lifesciences current liabilities as a starting point in their analysis.
ReShape Lifesciences Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
ReShape Liabilities And Stockholders Equity
Liabilities And Stockholders Equity |
|
In accordance with the recently published financial statements, ReShape Lifesciences has a Current Liabilities of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
ReShape Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ReShape Lifesciences' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ReShape Lifesciences could also be used in its relative valuation, which is a method of valuing ReShape Lifesciences by comparing valuation metrics of similar companies.ReShape Lifesciences is currently under evaluation in current liabilities category among its peers.
ReShape Lifesciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of ReShape Lifesciences from analyzing ReShape Lifesciences' financial statements. These drivers represent accounts that assess ReShape Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ReShape Lifesciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 17.6M | 17.9M | 2.9M | 1.5M | 1.7M | 1.6M | |
| Enterprise Value | 15.1M | (4.6M) | (823.6K) | (2.7M) | (3.1M) | (3.0M) |
ReShape Fundamentals
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.05) % | ||||
| Current Valuation | 1.6 M | ||||
| Shares Outstanding | 712.68 K | ||||
| Shares Owned By Insiders | 5.57 % | ||||
| Shares Owned By Institutions | 1.83 % | ||||
| Number Of Shares Shorted | 82.81 K | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 0.27 X | ||||
| Revenue | 8.68 M | ||||
| Gross Profit | 6.8 M | ||||
| EBITDA | (14.48 M) | ||||
| Net Income | (11.39 M) | ||||
| Cash And Equivalents | 11.49 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 262 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.12 X | ||||
| Book Value Per Share | 16.48 X | ||||
| Cash Flow From Operations | (16.96 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | 76.20 X | ||||
| Price To Earnings To Growth | (12.12) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 29 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 3.64 M | ||||
| Total Asset | 10.66 M | ||||
| Retained Earnings | (635.57 M) | ||||
| Working Capital | 6.52 M | ||||
| Net Asset | 10.66 M |
About ReShape Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ReShape Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ReShape Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ReShape Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.